Former Wyeth executive joins Ricerca Biosciences

Michael Placke takes position of senior vice president and general manager

Michael Placke will join Ricerca Biosciences as senior vice president and general manager at the CRO’s Concord, Ohio, facility on 24 May.

He will be responsible for the operations and business performance of Ricerca’s Concord site and will be working with the executive team participating in the global integration of Concord, Ohio, based services to the recently acquired DSA services in Lyon, France, and the pharmacology/DMPK services in Bothell, Washington and Taipei, Taiwan.

Prior to this position, Placke was vice president, drug safety, at Wyeth Research (now Pfizer) in Chazy, New York, where he was responsible for leading all non-clinical drug safety evaluations and support of Wyeth’s drug development portfolio from candidate selections through post-marketing assessment. Before joining Wyeth, he was with Battelle Pharma, in Columbus, Ohio, where he was vice president, pharmaceutical development, and chief scientist from 1999 to 2003.

You may also like

Research & Development

Celerion and Ricerca Biosciences to provide integrated service for biosimilars

Will test viability of a potential biosimilar early in the process
Research & Development

Ricerca announces similarity analysis service

Foresight allows compound assay results to be compared against pharmacologically active compounds
Research & Development

Ricerca and LSP agree business development collaboration

Ricerca will expand its presence in Japan, Korea and overall Asian market
Regulatory

Ricerca completes purchase of MDS Pharma businesses

The acquisition gives Ohio-based Ricerca more capacity and capabilities.
Research & Development

MDS to sell early stage business to Ricerca

MDS Pharma Services is to sell its remaining discovery and pre-clinical operations to Ohio-based Ricerca Biosciences for US$45m.
Research & Development

Poolbeg Pharma trial to feature in groundbreaking cancer immunotherapy-induced CRS research programme

Poolbeg will act as the lead business partner, alongside Johnson & Johnson and other partners, on the University of Manchester and The Christie NHS Foundation Trust research programme titled RISE (Reducing Immune Stress from Excess cytokine release in advanced therapies)
Research & Development

Lilly’s Jaypirca outperforms Imbruvica in landmark Phase III CLL trial, showing higher response rates and strong PFS trend

Pirtobrutinib met its primary endpoint and delivered higher overall response rates than ibrutinib in the BRUIN CLL-314 study, with early progression-free survival data also favouring Lilly’s next-generation BTK inhibitor
Subscribe now